1.4M XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| John Schmid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2025 | 20,645 | 0 | - | - | Stock Option (right to buy) | |
| John Schmid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.55 per share. | 13 Jan 2025 | 21,692 | 25,592 (0%) | 0% | 4.6 | 98,699 | Common Stock |
| John Schmid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.54 per share. | 13 Jan 2025 | 20,645 | 46,237 (0%) | 0% | 8.5 | 176,308 | Common Stock |
| John Schmid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2025 | 21,692 | 0 | - | - | Stock Option (right to buy) | |
| Dennis M. Fenton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| Dennis M. Fenton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 6,030 | 6,030 | - | - | Restricted Stock Unit | |
| Hollings C. Renton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| Hollings C. Renton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 6,030 | 6,030 | - | - | Restricted Stock Unit | |
| John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 6,030 | 6,030 | - | - | Restricted Stock Unit | |
| John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 6,030 | 6,030 | - | - | Restricted Stock Unit | |
| Magda Marquet | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| Magda Marquet | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 6,030 | 6,030 | - | - | Restricted Stock Unit | |
| Rita I. Jain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 6,030 | 6,030 | - | - | Restricted Stock Unit | |
| Rita I. Jain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| J. Anthony Ware | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| J. Anthony Ware | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 6,030 | 6,030 | - | - | Restricted Stock Unit | |
| Eric J. Loumeau | CHIEF LEGAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.60 per share. | 03 Jan 2025 | 2,994 | 7,675 (0%) | 0% | 14.6 | 43,712 | Common Stock |
| Eric J. Loumeau | CHIEF LEGAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.30 per share. | 03 Jan 2025 | 2,217 | 11,003 (0%) | 0% | 15.3 | 33,920 | Common Stock |
| Eric J. Loumeau | CHIEF LEGAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 7,288 | 21,862 | - | - | Restricted Stock Unit | |
| Eric J. Loumeau | CHIEF LEGAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 5,545 | 11,090 | - | - | Restricted Stock Unit | |
| Eric J. Loumeau | CHIEF LEGAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 23,550 | 23,550 | - | - | Restricted Stock Unit | |
| Eric J. Loumeau | CHIEF LEGAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 67,000 | 67,000 | - | - | Stock Option (right to buy) | |
| Eric J. Loumeau | CHIEF LEGAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 7,288 | 10,669 (0%) | 0% | - | Common Stock | |
| Eric J. Loumeau | CHIEF LEGAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 5,545 | 13,220 (0%) | 0% | - | Common Stock | |
| Dennis M. Mulroy | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.60 per share. | 03 Jan 2025 | 3,407 | 10,611 (0%) | 0% | 14.6 | 49,742 | Common Stock |
| Dennis M. Mulroy | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 8,293 | 14,018 (0%) | 0% | - | Common Stock | |
| Dennis M. Mulroy | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 8,293 | 24,877 | - | - | Restricted Stock Unit | |
| Dennis M. Mulroy | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 5,245 | 10,490 | - | - | Restricted Stock Unit | |
| Dennis M. Mulroy | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 26,800 | 26,800 | - | - | Restricted Stock Unit | |
| Dennis M. Mulroy | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 76,400 | 76,400 | - | - | Stock Option (right to buy) | |
| Dennis M. Mulroy | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.30 per share. | 03 Jan 2025 | 2,054 | 13,802 (0%) | 0% | 15.3 | 31,426 | Common Stock |
| Dennis M. Mulroy | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 5,245 | 15,856 (0%) | 0% | - | Common Stock | |
| Daniel R. Faga | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 107,350 | 107,350 | - | - | Restricted Stock Unit | |
| Daniel R. Faga | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 34,678 | 438,036 (1%) | 0% | - | Common Stock | |
| Daniel R. Faga | Director, President, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.60 per share. | 03 Jan 2025 | 13,033 | 425,003 (1%) | 0% | 14.6 | 190,282 | Common Stock |
| Daniel R. Faga | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 17,850 | 442,853 (1%) | 0% | - | Common Stock | |
| Daniel R. Faga | Director, President, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.30 per share. | 03 Jan 2025 | 6,387 | 436,466 (1%) | 0% | 15.3 | 97,721 | Common Stock |
| Daniel R. Faga | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 34,678 | 104,032 | - | - | Restricted Stock Unit | |
| Daniel R. Faga | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 17,850 | 35,700 | - | - | Restricted Stock Unit | |
| Daniel R. Faga | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 305,500 | 305,500 | - | - | Stock Option (right to buy) | |
| Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 97,200 | 97,200 | - | - | Stock Option (right to buy) | |
| Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2025 | 34,100 | 34,100 | - | - | Restricted Stock Unit | |
| Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 6,145 | 12,290 | - | - | Restricted Stock Unit | |
| Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 10,555 | 31,665 | - | - | Restricted Stock Unit | |
| Paul F. Lizzul | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.30 per share. | 03 Jan 2025 | 2,261 | 25,643 (0%) | 0% | 15.3 | 34,593 | Common Stock |
| Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 6,145 | 27,904 (0%) | 0% | - | Common Stock | |
| Paul F. Lizzul | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.60 per share. | 03 Jan 2025 | 4,336 | 21,759 (0%) | 0% | 14.6 | 63,306 | Common Stock |
| Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 10,555 | 26,095 (0%) | 0% | - | Common Stock | |
| Renton Hollings C. | Director | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 29 Nov 2024 | 10,000 | 1,950 (0%) | 0% | 25 | 250,000 | Common Stock |
| Renton Hollings C. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.93 per share. | 29 Nov 2024 | 10,000 | 11,950 (0%) | 0% | 6.9 | 69,300 | Common Stock |
| Hollings Renton C. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2024 | 10,000 | 20,925 | - | - | Common Stock | |
| Paul F. Lizzul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 38.67 per share. | 23 Sep 2024 | 1,500 | 15,398 (0%) | 0% | 38.7 | 58,005 | Common Stock |
| Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.50 per share. | 23 Sep 2024 | 1,500 | 16,898 (0%) | 0% | 18.5 | 27,750 | Common Stock |
| Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Sep 2024 | 1,500 | 85,000 | - | - | Common | |
| John A. Orwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2024 | 1,300 | 2,600 | - | - | Restricted Stock Unit | |
| John A. Orwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2024 | 1,300 | 3,335 (0%) | 0% | 0 | Common Stock | |
| Eric J. Loumeau | CHIEF LEGAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 6,000 | 0 | - | - | Restricted Stock Unit | |
| Eric J. Loumeau | CHIEF LEGAL OFFICER | Sale of securities on an exchange or to another person at price $ 38.41 per share. | 14 Sep 2024 | 3,780 | 3,240 (0%) | 0% | 38.4 | 145,191 | Common Stock |
| Eric J. Loumeau | CHIEF LEGAL OFFICER | Sale of securities on an exchange or to another person at price $ 40.13 per share. | 14 Sep 2024 | 6,500 | 7,020 (0%) | 0% | 40.1 | 260,845 | Common Stock |
| Eric J. Loumeau | CHIEF LEGAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.02 per share. | 14 Sep 2024 | 5,000 | 13,520 (0%) | 0% | 14.0 | 70,100 | Common Stock |
| Eric J. Loumeau | CHIEF LEGAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 6,000 | 10,740 (0%) | 0% | 0 | Common Stock | |
| Eric J. Loumeau | CHIEF LEGAL OFFICER | Sale of securities on an exchange or to another person at price $ 38.93 per share. | 14 Sep 2024 | 2,220 | 8,520 (0%) | 0% | 38.9 | 86,425 | Common Stock |
| Eric J. Loumeau | CHIEF LEGAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 5,000 | 73,000 | - | - | Employee Stock Option (right to buy) | |
| Dennis M. Mulroy | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 38.93 per share. | 14 Sep 2024 | 2,220 | 4,744 (0%) | 0% | 38.9 | 86,425 | Common Stock |
| Dennis M. Mulroy | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 10,000 | 80,600 | - | - | Employee Stock Option (right to buy) | |
| Dennis M. Mulroy | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 6,000 | 0 | - | - | Restricted Stock Unit | |
| Dennis M. Mulroy | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 40.13 per share. | 14 Sep 2024 | 10,000 | 4,744 (0%) | 0% | 40.1 | 401,300 | Common Stock |
| Dennis M. Mulroy | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.16 per share. | 14 Sep 2024 | 10,000 | 14,744 (0%) | 0% | 20.2 | 201,600 | Common Stock |
| Dennis M. Mulroy | CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 6,000 | 6,964 (0%) | 0% | - | Common Stock | |
| Paul F. Lizzul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 38.93 per share. | 14 Sep 2024 | 2,220 | 15,398 (0%) | 0% | 38.9 | 86,425 | Common Stock |
| Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 6,000 | 0 | - | - | Restricted Stock Unit | |
| Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 6,000 | 17,618 (0%) | 0% | - | Common Stock | |
| Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.50 per share. | 14 Aug 2024 | 2,000 | 13,618 (0%) | 0% | 18.5 | 37,000 | Common Stock |
| Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Aug 2024 | 2,000 | 86,500 | - | - | Common | |
| Paul F. Lizzul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 14 Aug 2024 | 2,000 | 11,618 (0%) | 0% | 40 | 80,000 | Common Stock |
| Eric J. Loumeau | CHIEF LEGAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2024 | 20,000 | 20,000 | - | - | Common Stock | |
| Dennis M. Mulroy | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2024 | 20,000 | 20,000 | - | - | Common Stock | |
| Daniel R. Faga | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2024 | 160,000 | 160,000 | - | - | Common Stock | |
| Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2024 | 50,000 | 50,000 | - | - | Common Stock | |
| Paul F. Lizzul | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 18 Jul 2024 | 1,500 | 11,618 (0%) | 0% | 35 | 52,500 | Common Stock |
| Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jul 2024 | 1,500 | 88,500 | - | - | Common | |
| Paul F. Lizzul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.50 per share. | 18 Jul 2024 | 1,500 | 13,118 (0%) | 0% | 18.5 | 27,750 | Common Stock |
| Hollings C. Renton | Director | Sale of securities on an exchange or to another person at price $ 30.50 per share. | 15 Jul 2024 | 7,103 | 4,847 (0%) | 0% | 30.5 | 216,668 | Common Stock |
| Hollings C. Renton | Director | Sale of securities on an exchange or to another person at price $ 30.98 per share. | 15 Jul 2024 | 2,897 | 1,950 (0%) | 0% | 31.0 | 89,754 | Common Stock |
| Hollings C. Renton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 10,000 | 30,925 | - | - | Common Stock | |
| Hollings C. Renton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.93 per share. | 15 Jul 2024 | 10,000 | 11,950 (0%) | 0% | 6.9 | 69,300 | Common Stock |
| Dennis M. Fenton | Director | Sale of securities on an exchange or to another person at price $ 23.17 per share. | 21 Jun 2024 | 1,950 | 1,950 (0%) | 0% | 23.2 | 45,182 | Common Stock |
| Dennis M. Fenton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 3,900 | 3,900 (0%) | 0% | 0 | Common Stock | |
| Dennis M. Fenton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 3,900 | 0 | - | - | Restricted Stock Unit | |
| Hollings C. Renton | Director | Sale of securities on an exchange or to another person at price $ 23.16 per share. | 15 Jun 2024 | 1,950 | 1,950 (0%) | 0% | 23.2 | 45,162 | Common Stock |
| Hollings C. Renton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 3,900 | 0 | - | - | Restricted Stock Unit | |
| Hollings C. Renton | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 3,900 | 3,900 (0%) | 0% | 0 | Common Stock | |
| John A. Orwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 2,035 | 0 | - | - | Restricted Stock Unit | |
| John A. Orwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 2,035 | 2,035 (0%) | 0% | 0 | Common Stock | |
| John Schmid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 3,900 | 0 | - | - | Restricted Stock Unit | |
| John Schmid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 3,900 | 3,900 (0%) | 0% | 0 | Common Stock | |
| Magda Marquet | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 3,900 | 0 | - | - | Restricted Stock Unit | |
| Magda Marquet | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 3,900 | 3,900 (0%) | 0% | 0 | Common Stock | |
| Rita I. Jain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 4,534 | 4,534 (0%) | 0% | 0 | Common Stock | |
| Rita I. Jain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 3,234 | 0 | - | - | Restricted Stock Unit | |
| Rita I. Jain | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 1,300 | 0 | - | - | Restricted Stock Unit | |
| J. Anthony Ware | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 3,900 | 0 | - | - | Restricted Stock Unit | |
| J. Anthony Ware | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 3,900 | 7,500 (0%) | 0% | 0 | Common Stock | |
| Dennis M. Mulroy | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 23.72 per share. | 22 May 2024 | 1,500 | 964 (0%) | 0% | 23.7 | 35,580 | Common Stock |
| Daniel R. Faga | Director, CEO | Sale of securities on an exchange or to another person at price $ 21.42 per share. | 22 Mar 2024 | 3,000 | 749,087 (2%) | 0% | 21.4 | 64,268 | Common Stock |
| Daniel R. Faga | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.60 per share. | 22 Mar 2024 | 347,441 | 401,646 (1%) | 1% | 21.6 | 7,504,726 | Common Stock |
| Daniel R. Faga | Director, CEO | Sale of securities on an exchange or to another person at price $ 22.78 per share. | 22 Mar 2024 | 145,940 | 752,087 (2%) | 0% | 22.8 | 3,325,185 | Common Stock |
| J. Loumeau Eric | CHIEF LEGAL OFFICER | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 16 Feb 2024 | 5,000 | 3,240 (0%) | 0% | 25 | 125,000 | Common Stock |
| Loumeau Eric J. | CHIEF LEGAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.02 per share. | 16 Feb 2024 | 5,000 | 8,240 (0%) | 0% | 14.0 | 70,100 | Common Stock |
| Loumeau Eric J. | CHIEF LEGAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 5,000 | 78,000 | - | - | Employee Stock Option (right to buy) | |
| M. Mulroy Dennis | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 23.63 per share. | 30 Jan 2024 | 3,065 | 964 (0%) | 0% | 23.6 | 72,425 | Common Stock |
| M. Dennis Mulroy | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2024 | 5,245 | 6,209 (0%) | 0% | 0 | Common Stock | |
| Dennis M. Mulroy | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.81 per share. | 06 Jan 2024 | 2,180 | 4,029 (0%) | 0% | 21.8 | 47,546 | Common Stock |
| Lizzul F. Paul | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2024 | 6,145 | 18,435 | - | - | Restricted Stock Unit | |
| Eric Loumeau J. | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 21.81 per share. | 06 Jan 2024 | 2,305 | 3,240 (0%) | 0% | 21.8 | 50,272 | Common Stock |
| J. Loumeau Eric | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2024 | 5,545 | 16,635 | - | - | Restricted Stock Unit | |
| Dennis M. Mulroy | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2024 | 5,245 | 15,735 | - | - | Restricted Stock Unit | |
| Daniel Faga R. | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2024 | 17,850 | 904,893 (3%) | 0% | 0 | Common Stock | |
| Eric Loumeau J. | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2024 | 5,545 | 5,545 (0%) | 0% | 0 | Common Stock | |
| Daniel R. Faga | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2024 | 17,850 | 53,550 | - | - | Restricted Stock Unit | |
| Paul Lizzul F. | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 21.81 per share. | 06 Jan 2024 | 2,554 | 10,118 (0%) | 0% | 21.8 | 55,703 | Common Stock |
| Lizzul Paul F. | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2024 | 6,145 | 12,672 (0%) | 0% | 0 | Common Stock | |
| Daniel R. Faga | Director, CEO | Sale of securities on an exchange or to another person at price $ 21.81 per share. | 06 Jan 2024 | 6,866 | 898,027 (3%) | 0% | 21.8 | 149,747 | Common Stock |
| Schmid John | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| M. Mulroy Dennis | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 90,780 | 90,780 | - | - | Stock Option (right to buy) | |
| C. Hollings Renton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 6,030 | 6,030 | - | - | Restricted Stock Unit | |
| Marquet Magda | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 6,030 | 6,030 | - | - | Restricted Stock Unit | |
| Lizzul Paul F. | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 115,540 | 115,540 | - | - | Stock Option (right to buy) | |
| I. Rita Jain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 6,030 | 6,030 | - | - | Restricted Stock Unit | |
| John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| J. Eric Loumeau | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 29,150 | 29,150 | - | - | Restricted Stock Unit | |
| Mulroy Dennis M. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 33,170 | 33,170 | - | - | Restricted Stock Unit | |
| R. Daniel Faga | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 379,620 | 379,620 | - | - | Stock Option (right to buy) | |
| Marquet Magda | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| R. Faga Daniel | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 138,710 | 138,710 | - | - | Restricted Stock Unit | |
| Jain Rita I. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| Dennis Fenton M. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 6,030 | 6,030 | - | - | Restricted Stock Unit | |
| M. Fenton Dennis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 6,030 | 6,030 | - | - | Restricted Stock Unit | |
| Ware J. Anthony | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 6,030 | 6,030 | - | - | Restricted Stock Unit | |
| Renton C. Hollings | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| A. John Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 6,030 | 6,030 | - | - | Restricted Stock Unit | |
| J. Eric Loumeau | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 79,780 | 79,780 | - | - | Stock Option (right to buy) | |
| Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 42,220 | 42,220 | - | - | Restricted Stock Unit | |
| Ware J. Anthony | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| Rita I. Jain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 3,234 | 3,234 | - | - | Restricted Stock Unit | |
| Rita I. Jain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 3,900 | 3,900 | - | - | Restricted Stock Unit | |
| Rita I. Jain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 8,015 | 8,015 | - | - | Stock Option (right to buy) | |
| Rita I. Jain | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 10,600 | 10,600 | - | - | Stock Option (right to buy) | |
| Eric J. Loumeau | COO, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 22,180 | 22,180 | - | - | Restricted Stock Unit | |
| Eric J. Loumeau | COO, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 60,530 | 60,530 | - | - | Stock Option (right to buy) | |
| Dennis M. Fenton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 10,600 | 10,600 | - | - | Stock Option (right to buy) | |
| Dennis M. Fenton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 3,900 | 3,900 | - | - | Restricted Stock Unit | |
| Hollings C. Renton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 10,600 | 10,600 | - | - | Stock Option (right to buy) | |
| Hollings C. Renton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 3,900 | 3,900 | - | - | Restricted Stock Unit | |
| James N. Topper | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 3,900 | 3,900 | - | - | Restricted Stock Unit | |
| James N. Topper | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 10,600 | 10,600 | - | - | Stock Option (right to buy) | |
| Dennis M. Mulroy | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 20,980 | 20,980 | - | - | Restricted Stock Unit | |
| Dennis M. Mulroy | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 57,260 | 57,260 | - | - | Stock Option (right to buy) | |
| John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 10,600 | 10,600 | - | - | Stock Option (right to buy) | |
| John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 3,900 | 3,900 | - | - | Restricted Stock Unit | |
| Magda Marquet | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 3,900 | 3,900 | - | - | Restricted Stock Unit | |
| Magda Marquet | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 10,600 | 10,600 | - | - | Stock Option (right to buy) | |
| Daniel R. Faga | Director, Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 194,900 | 194,900 | - | - | Stock Option (right to buy) | |
| Daniel R. Faga | Director, Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 71,400 | 71,400 | - | - | Restricted Stock Unit | |
| Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 24,580 | 24,580 | - | - | Restricted Stock Unit | |
| Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 67,070 | 67,070 | - | - | Stock Option (right to buy) | |
| J. Anthony Ware | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 10,600 | 10,600 | - | - | Stock Option (right to buy) | |
| J. Anthony Ware | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 3,900 | 3,900 | - | - | Restricted Stock Unit | |
| Laura J. Hamill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 10,600 | 10,600 | - | - | Stock Option (right to buy) | |
| Laura J. Hamill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 3,900 | 3,900 | - | - | Restricted Stock Unit | |
| Eric J. Loumeau | COO, General Counsel | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 08 Aug 2022 | 523 | 0 (0%) | 0% | 25 | 13,075 | Common Stock |
| Eric J. Loumeau | COO, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Dennis M. Mulroy | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Eric J. Loumeau | COO, General Counsel | Sale of securities on an exchange or to another person at price $ 24.00 per share. | 08 Jun 2022 | 2,500 | 523 (0%) | 0% | 24 | 60,000 | Common Stock |
| Eric J. Loumeau | COO, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2022 | 2,500 | 83,000 | - | - | Employee Stock Option (Right to Buy) | |
| Eric J. Loumeau | COO, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.02 per share. | 08 Jun 2022 | 2,500 | 3,023 (0%) | 0% | 14.0 | 35,050 | Common Stock |
| Eric J. Loumeau | COO, General Counsel | Sale of securities on an exchange or to another person at price $ 20.50 per share. | 18 May 2022 | 1,146 | 523 (0%) | 0% | 20.5 | 23,493 | Common Stock |
| Daniel R. Faga | Director, Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2022 | 887,043 | 887,043 (3%) | 3% | 0 | Common Stock | |
| Eric J. Loumeau | COO, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Dennis M. Fenton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 9,200 | 9,200 | - | - | Stock Option (right to buy) | |
| Hollings C. Renton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 9,200 | 9,200 | - | - | Stock Option (right to buy) | |
| James N. Topper | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 9,200 | 9,200 | - | - | Stock Option (right to buy) | |
| Dennis M. Mulroy | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 9,200 | 9,200 | - | - | Stock Option (right to buy) | |
| Magda Marquet | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 9,200 | 9,200 | - | - | Stock Option (right to buy) | |
| Daniel R. Faga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 9,200 | 9,200 | - | - | Stock Option (right to buy) | |
| Hamza Suria | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| J. Anthony Ware | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 9,200 | 9,200 | - | - | Stock Option (right to buy) | |
| Laura J. Hamill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 9,200 | 9,200 | - | - | Stock Option (right to buy) | |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 35.75 per share. | 20 Dec 2021 | 19,208 | 74,122 (0%) | 0% | 35.8 | 686,776 | Common Stock |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2021 | 36,645 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 36.40 per share. | 20 Dec 2021 | 5,522 | 68,600 (0%) | 0% | 36.4 | 201,026 | Common Stock |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 34.89 per share. | 20 Dec 2021 | 11,915 | 93,330 (0%) | 0% | 34.9 | 415,756 | Common Stock |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 20 Dec 2021 | 36,645 | 105,245 (0%) | 0% | 1.1 | 41,042 | Common Stock |
| Daniel R. Faga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Nov 2021 | 11,000 | 11,000 | - | - | Stock Option (Right to Buy) | |
| Daniel R. Faga | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Nov 2021 | 2,321 | 2,321 | - | - | Stock Option (Right to Buy) | |
| Eric J. Loumeau | COO, General Counsel | Grant, award, or other acquisition of securities at price $ 22.03 per share. | 15 Nov 2021 | 523 | 523 (0%) | 0% | 22.0 | 11,522 | Common Stock |
| Dennis M. Mulroy | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 22.03 per share. | 15 Nov 2021 | 964 | 964 (0%) | 0% | 22.0 | 21,237 | Common Stock |
| Hamza Suria | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 22.03 per share. | 15 Nov 2021 | 964 | 68,600 (0%) | 0% | 22.0 | 21,237 | Common Stock |
| Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 22.03 per share. | 15 Nov 2021 | 964 | 964 (0%) | 0% | 22.0 | 21,237 | Common Stock |
| Eric J. Loumeau | COO, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.16 per share. | 04 Nov 2021 | 2,500 | 5,000 (0%) | 0% | 20.2 | 50,400 | Common Stock |
| Eric J. Loumeau | COO, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2021 | 2,500 | 7,500 | - | - | Employee Stock Option (Right to Buy) | |
| Eric J. Loumeau | COO, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2021 | 2,500 | 85,500 | - | - | Employee Stock Option (Right to Buy) | |
| Eric J. Loumeau | COO, General Counsel | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 04 Nov 2021 | 5,000 | 0 (0%) | 0% | 35 | 175,000 | Common Stock |
| Eric J. Loumeau | COO, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.02 per share. | 04 Nov 2021 | 2,500 | 2,500 (0%) | 0% | 14.0 | 35,050 | Common Stock |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 04 Nov 2021 | 6,059 | 67,636 (0%) | 0% | 35 | 212,065 | Common Stock |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 04 Nov 2021 | 6,059 | 73,695 (0%) | 0% | 1.1 | 6,786 | Common Stock |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2021 | 14,302 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Nov 2021 | 6,059 | 14,302 | - | - | Employee Stock Option (Right to Buy) | |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 04 Nov 2021 | 14,302 | 67,636 (0%) | 0% | 35 | 500,570 | Common Stock |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 04 Nov 2021 | 14,302 | 81,938 (0%) | 0% | 1.1 | 16,018 | Common Stock |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 32.27 per share. | 01 Nov 2021 | 34,087 | 70,195 (0%) | 0% | 32.3 | 1,099,967 | Common Stock |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 01 Nov 2021 | 36,646 | 104,282 (0%) | 0% | 1.1 | 41,044 | Common Stock |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 32.88 per share. | 01 Nov 2021 | 2,559 | 67,636 (0%) | 0% | 32.9 | 84,139 | Common Stock |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 36,646 | 36,645 | - | - | Employee Stock Option (right to buy) | |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Oct 2021 | 15,993 | 73,291 | - | - | Employee Stock Option (right to buy) | |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 26 Oct 2021 | 15,993 | 67,636 (0%) | 0% | 30 | 479,790 | Common Stock |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 26 Oct 2021 | 15,993 | 83,629 (0%) | 0% | 1.1 | 17,912 | Common Stock |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 17 Sep 2021 | 10,000 | 67,636 (0%) | 0% | 1.1 | 11,200 | Common Stock |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Sep 2021 | 10,000 | 20,361 | - | - | Employee Stock Option (right to buy) | |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 12 May 2021 | 10,000 | 57,636 (0%) | 0% | 1.1 | 11,200 | Common Stock |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 May 2021 | 10,000 | 30,361 | - | - | Employee Stock Option (right to buy) | |
| Eric J. Loumeau | COO, General Counsel | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 10 Feb 2021 | 10,000 | 0 (0%) | 0% | 35 | 350,000 | Common Stock |
| Eric J. Loumeau | COO, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2021 | 10,000 | 88,000 | - | - | Stock Option (right to buy) | |
| Eric J. Loumeau | COO, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Eric J. Loumeau | COO, General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.02 per share. | 10 Feb 2021 | 10,000 | 10,000 (0%) | 0% | 14.0 | 140,200 | Common Stock |
| Dennis M. Fenton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Hollings C. Renton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| James N. Topper | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Dennis M. Mulroy | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Magda Marquet | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Hamza Suria | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 119,700 | 119,700 | - | - | Stock Option (right to buy) | |
| Paul F. Lizzul | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| J. Anthony Ware | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Laura Hamill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Magda Marquet | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2021 | 784 | 784 | - | - | Stock Option (right to buy) | |
| Magda Marquet | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2021 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| Eric J. Loumeau | COO, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jul 2020 | 10,000 | 10,000 | - | - | Employee Stock Option (Right to Buy) | |
| Dennis M. Mulroy | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jul 2020 | 90,600 | 90,600 | - | - | Employee Stock Option (Right to Buy) | |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 10 Mar 2020 | 10,000 | 47,636 (0%) | 0% | 1.1 | 11,200 | Common Stock |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2020 | 10,000 | 40,361 | - | - | Employee Stock Option (Right to Buy) | |
| Dennis M. Fenton | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2020 | 11,000 | 11,000 | - | - | Director Stock Option (Right to Buy) | |
| Hollings C. Renton | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2020 | 11,000 | 11,000 | - | - | Director Stock Option (Right to Buy) | |
| James N. Topper | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2020 | 11,000 | 11,000 | - | - | Director Stock Option (Right to Buy) | |
| John Schmid | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2020 | 11,000 | 11,000 | - | - | Director Stock Option (Right to Buy) | |
| J. Anthony Ware | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2020 | 11,000 | 11,000 | - | - | Director Stock Option (Right to Buy) | |
| Laura Hamill | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2020 | 11,000 | 11,000 | - | - | Director Stock Option (Right to Buy) | |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 05 Feb 2020 | 10,000 | 37,636 (0%) | 0% | 1.1 | 11,200 | Common Stock |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2020 | 10,000 | 50,361 | - | - | Employee Stock Option (Right to Buy) | |
| Hamza Suria | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2019 | 280,000 | 280,000 | - | - | Employee Stock Option (Right to Buy) | |
| J. Anthony Ware | Director | Purchase of securities on an exchange or from another person at price $ 14.05 per share. | 10 Dec 2019 | 3,600 | 3,600 (0%) | 0% | 14.1 | 50,580 | Common Stock |
| Eric J. Loumeau | General Counsel & Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2019 | 98,000 | 98,000 | - | - | Employee Stock Option (Right to Buy) | |
| Marco Londei | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Dec 2019 | 98,000 | 98,000 | - | - | Employee Stock Option (Right to Buy) | |
| Marco Londei | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.93 per share. | 27 Nov 2019 | 46,202 | 68,579 (0%) | 0% | 6.9 | 320,180 | Common Stock |
| Marco Londei | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Nov 2019 | 46,202 | 4,946 | - | - | Employee Stock Option (Right to Buy) | |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Nov 2019 | 10,000 | 60,361 | - | - | Employee Stock Option (Right to Buy) | |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 22 Nov 2019 | 10,000 | 27,636 (0%) | 0% | 1.1 | 11,200 | Common Stock |
| Laura J. Hamill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2019 | 2,268 | 2,268 | - | - | Director Stock Option (Right to Buy) | |
| Laura J. Hamill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2019 | 6,000 | 6,000 | - | - | Director Stock Option (Rigth to Buy) | |
| Eric J. Loumeau | General Counsel & Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2019 | 17,500 | 17,500 | - | - | Employee Stock Option (Right to Buy) | |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 73.70 per share. | 10 Jun 2019 | 6,440 | 25,084 (0%) | 0% | 73.7 | 474,637 | Common Stock |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 76.31 per share. | 10 Jun 2019 | 454 | 17,636 (0%) | 0% | 76.3 | 34,645 | Common Stock |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 75.86 per share. | 10 Jun 2019 | 1,994 | 18,090 (0%) | 0% | 75.9 | 151,271 | Common Stock |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 74.68 per share. | 10 Jun 2019 | 5,000 | 20,084 (0%) | 0% | 74.7 | 373,413 | Common Stock |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 72.64 per share. | 10 Jun 2019 | 8,540 | 31,524 (0%) | 0% | 72.6 | 620,385 | Common Stock |
| Marco Londei | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.70 per share. | 04 Jun 2019 | 10,060 | 32,437 (0%) | 0% | 0.7 | 7,042 | Common Stock |
| Marco Londei | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 72.45 per share. | 04 Jun 2019 | 6,009 | 26,428 (0%) | 0% | 72.5 | 435,359 | Common Stock |
| Marco Londei | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 73.43 per share. | 04 Jun 2019 | 2,048 | 24,380 (0%) | 0% | 73.4 | 150,384 | Common Stock |
| Marco Londei | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 74.50 per share. | 04 Jun 2019 | 2,003 | 22,377 (0%) | 0% | 74.5 | 149,219 | Common Stock |
| Marco Londei | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2019 | 10,060 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Apr 2019 | 10,000 | 70,361 | - | - | Employee Stock Option (Right to Buy) | |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 17 Apr 2019 | 10,000 | 40,064 (0%) | 0% | 1.1 | 11,200 | Common Stock |
| Eric J. Loumeau | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2019 | 35,000 | 35,000 | - | - | Employee Stock Option (Right to Buy) | |
| Dennis M. Fenton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2019 | 6,000 | 6,000 | - | - | Director Stock Option (Right to Buy) | |
| Hollings C. Renton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2019 | 6,000 | 6,000 | - | - | Director Stock Option (Right to Buy) | |
| James N. Topper | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2019 | 6,000 | 6,000 | - | - | Director Stock Option (Right to Buy) | |
| John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2019 | 6,000 | 6,000 | - | - | Director Stock Option (Right to Buy) | |
| Nicholas Lydon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2019 | 6,000 | 6,000 | - | - | Director Stock Option (Right to Buy) | |
| Hamza Suria | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2019 | 94,000 | 94,000 | - | - | Employee Stock Option (Right to Buy) | |
| Marco Londei | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2019 | 35,000 | 35,000 | - | - | Employee Stock Option (Right to Buy) | |
| Dominic G. Piscitelli | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2019 | 35,000 | 35,000 | - | - | Employee Stock Option (Right to Buy) | |
| J. Anthony Ware | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2019 | 6,000 | 6,000 | - | - | Director Stock Option (Right to Buy) | |
| Marco Londei | Chief Medical Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 15 Jan 2019 | 122,500 | 22,377 (0%) | 0% | 0 | Common Stock | |
| Marco Londei | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 70.04 per share. | 15 Jan 2019 | 14,894 | 22,377 (0%) | 0% | 70.0 | 1,043,195 | Common Stock |
| Marco Londei | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 69.29 per share. | 15 Jan 2019 | 4,181 | 37,271 (0%) | 0% | 69.3 | 289,686 | Common Stock |
| Marco Londei | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.93 per share. | 15 Jan 2019 | 19,075 | 41,452 (0%) | 0% | 6.9 | 132,190 | Common Stock |
| Marco Londei | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jan 2019 | 19,075 | 51,148 | - | - | Employee Stock Option (Right to Buy) | |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 70.65 per share. | 14 Jan 2019 | 27,760 | 42,304 (0%) | 0% | 70.6 | 1,961,227 | Common Stock |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 71.10 per share. | 14 Jan 2019 | 12,240 | 30,064 (0%) | 0% | 71.1 | 870,304 | Common Stock |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2019 | 40,000 | 89,284 | - | - | Employee Stock Option (Right to Buy) | |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 14 Jan 2019 | 40,000 | 70,064 (0%) | 0% | 1.1 | 44,800 | Common Stock |
| Marco Londei | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.70 per share. | 17 Dec 2018 | 8,048 | 152,925 (0%) | 0% | 0.7 | 5,634 | Common Stock |
| Marco Londei | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.93 per share. | 17 Dec 2018 | 22,000 | 174,925 (0%) | 0% | 6.9 | 152,460 | Common Stock |
| Marco Londei | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 65.36 per share. | 17 Dec 2018 | 12,120 | 162,805 (0%) | 0% | 65.4 | 792,178 | Common Stock |
| Marco Londei | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 66.38 per share. | 17 Dec 2018 | 3,185 | 159,620 (0%) | 0% | 66.4 | 211,416 | Common Stock |
| Marco Londei | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 67.57 per share. | 17 Dec 2018 | 8,002 | 151,618 (0%) | 0% | 67.6 | 540,684 | Common Stock |
| Marco Londei | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 68.47 per share. | 17 Dec 2018 | 6,741 | 144,877 (0%) | 0% | 68.5 | 461,578 | Common Stock |
| Marco Londei | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2018 | 8,048 | 10,060 | - | - | Employee Stock Option (Right to Buy) | |
| Marco Londei | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2018 | 22,000 | 70,223 | - | - | Employee Stock Option (Right to Buy) | |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2018 | 41,728 | 129,284 | - | - | Employee Stock Option (Right to Buy) | |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 14 Dec 2018 | 41,728 | 71,792 (0%) | 0% | 1.1 | 46,735 | Common Stock |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 68.89 per share. | 14 Dec 2018 | 24,844 | 46,948 (0%) | 0% | 68.9 | 1,711,429 | Common Stock |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 69.68 per share. | 14 Dec 2018 | 9,084 | 37,864 (0%) | 0% | 69.7 | 632,968 | Common Stock |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 70.51 per share. | 14 Dec 2018 | 7,800 | 30,064 (0%) | 0% | 70.5 | 549,979 | Common Stock |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 10 Dec 2018 | 30,000 | 60,064 (0%) | 0% | 1.1 | 33,600 | Common Stock |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 71.11 per share. | 10 Dec 2018 | 12,003 | 48,061 (0%) | 0% | 71.1 | 853,481 | Common Stock |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 71.92 per share. | 10 Dec 2018 | 9,673 | 38,388 (0%) | 0% | 71.9 | 695,718 | Common Stock |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 72.88 per share. | 10 Dec 2018 | 8,324 | 30,064 (0%) | 0% | 72.9 | 606,618 | Common Stock |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2018 | 30,587 | 110,361 | - | - | Employee Stock Option (Right to Buy) | |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2018 | 30,000 | 80,361 | - | - | Employee Stock Option | |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 10 Dec 2018 | 30,587 | 65,649 (0%) | 0% | 1.1 | 34,257 | Common Stock |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 70.57 per share. | 10 Dec 2018 | 15,276 | 50,373 (0%) | 0% | 70.6 | 1,078,082 | Common Stock |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 71.49 per share. | 10 Dec 2018 | 10,347 | 40,026 (0%) | 0% | 71.5 | 739,701 | Common Stock |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 72.48 per share. | 10 Dec 2018 | 4,964 | 35,062 (0%) | 0% | 72.5 | 359,805 | Common Stock |
| Hamza Suria | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 70.83 per share. | 10 Dec 2018 | 4,998 | 30,064 (0%) | 0% | 70.8 | 354,008 | Common Stock |
| Dominic G. Piscitelli | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2018 | 37,000 | 133,241 | - | - | Employee Stock Option (Right to Buy) | |
| Dominic G. Piscitelli | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 70.34 per share. | 03 Dec 2018 | 3,554 | 33,446 (0%) | 0% | 70.3 | 249,974 | Common Stock |
| Dominic G. Piscitelli | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 71.33 per share. | 03 Dec 2018 | 18,604 | 14,842 (0%) | 0% | 71.3 | 1,327,061 | Common Stock |
| Dominic G. Piscitelli | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 72.24 per share. | 03 Dec 2018 | 4,820 | 10,022 (0%) | 0% | 72.2 | 348,212 | Common Stock |
| Dominic G. Piscitelli | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 73.18 per share. | 03 Dec 2018 | 2,298 | 7,724 (0%) | 0% | 73.2 | 168,159 | Common Stock |
| Dominic G. Piscitelli | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 74.33 per share. | 03 Dec 2018 | 6,624 | 1,100 (0%) | 0% | 74.3 | 492,362 | Common Stock |
| Dominic G. Piscitelli | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 75.81 per share. | 03 Dec 2018 | 1,100 | 0 (0%) | 0% | 75.8 | 83,390 | Common Stock |
| Dominic G. Piscitelli | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.34 per share. | 03 Dec 2018 | 37,000 | 37,000 (0%) | 0% | 11.3 | 419,580 | Common Stock |
| Marco Londei | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.70 per share. | 07 Sep 2018 | 142,857 | 144,877 (0%) | 0% | 0.7 | 100,000 | Common Stock |
| Marco Londei | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2018 | 142,857 | 18,108 | - | - | Employee Stock Option (right to buy) | |
| Eric J. Loumeau | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2018 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jul 2018 | 1,428 | 0 | - | - | Employee Stock Option (right to buy) | |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.61 per share. | 09 Jul 2018 | 6,208 | 35,062 (0%) | 0% | 1.6 | 9,995 | Common Stock |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.24 per share. | 09 Jul 2018 | 1,428 | 28,854 (0%) | 0% | 2.2 | 3,199 | Common Stock |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jul 2018 | 6,208 | 0 | - | - | Employee Stock Option (right to buy) | |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.59 per share. | 08 Jun 2018 | 22,428 | 27,426 (0%) | 0% | 2.6 | 58,089 | Common Stock |
| Hamza Suria | Director, President, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2018 | 22,428 | 0 | - | - | Employee Stock Option (right to buy) | |
| James N. Topper | None | Other type of transaction at price $ 0.00 per share. | 11 May 2018 | 301,024 | 301,024 (1%) | 1% | 0 | Common Stock | |
| James N. Topper | None | Other type of transaction at price $ 0.00 per share. | 11 May 2018 | 1,372,000 | 973,612 (4%) | 5% | 0 | Common Stock | |
| James N. Topper | None | Other type of transaction at price $ 0.00 per share. | 11 May 2018 | 31,854 | 31,854 (0%) | 0% | 0 | Common Stock | |
| James N. Topper | None | Other type of transaction at price $ 0.00 per share. | 11 May 2018 | 301,024 | 0 (0%) | 1% | 0 | Common Stock | |
| Nicholas Lydon | None | Sale of securities on an exchange or to another person at price $ 86.15 per share. | 16 Apr 2018 | 1,390 | 289,806 (1%) | 0% | 86.2 | 119,753 | Common Stock |
| Nicholas Lydon | None | Sale of securities on an exchange or to another person at price $ 84.18 per share. | 16 Apr 2018 | 2,600 | 301,506 (1%) | 0% | 84.2 | 218,880 | Common Stock |
| Nicholas Lydon | None | Sale of securities on an exchange or to another person at price $ 85.11 per share. | 16 Apr 2018 | 10,310 | 291,196 (1%) | 0% | 85.1 | 877,491 | Common Stock |
| Nicholas Lydon | None | Sale of securities on an exchange or to another person at price $ 87.46 per share. | 16 Apr 2018 | 9,425 | 280,381 (1%) | 0% | 87.5 | 824,341 | Common Stock |
| Nicholas Lydon | None | Sale of securities on an exchange or to another person at price $ 88.30 per share. | 16 Apr 2018 | 4,250 | 276,131 (1%) | 0% | 88.3 | 375,267 | Common Stock |
| Nicholas Lydon | None | Sale of securities on an exchange or to another person at price $ 89.42 per share. | 16 Apr 2018 | 2,803 | 273,328 (1%) | 0% | 89.4 | 250,631 | Common Stock |
| Nicholas Lydon | None | Sale of securities on an exchange or to another person at price $ 90.26 per share. | 16 Apr 2018 | 2,222 | 271,106 (1%) | 0% | 90.3 | 200,549 | Common Stock |
| Dennis M. Fenton | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2018 | 6,000 | 6,000 | - | - | Director Stock Option (right to buy) | |
| Dennis M. Fenton | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2018 | 5,507 | 5,507 | - | - | Director Stock Option (right to buy) | |
| Nicholas Lydon | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2018 | 16,483 | 0 | - | - | Series C Preferred Stock Warrant (right to buy) | |
| Nicholas Lydon | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.55 per share. | 15 Feb 2018 | 16,483 | 304,106 (1%) | 0% | 4.6 | 74,998 | Common Stock |
| Hamza Suria | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2018 | 63,000 | 63,000 | - | - | Employee Stock Option (right to buy) | |
| Marco Londei | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2018 | 28,000 | 28,000 | - | - | Employee Stock Option (right to buy) | |
| Dominic G. Piscitelli | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2018 | 23,000 | 23,000 | - | - | Employee Stock Option (right to buy) | |
| J. Anthony Ware | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Aug 2017 | 28,571 | 28,571 | - | - | Director Stock Option (right to buy) | |
| J. Anthony Ware | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Aug 2017 | 10,694 | 10,694 | - | - | Director Stock Option (right to buy) | |
| Carol G. Gallagher | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2017 | 15,000 | 15,000 | - | - | Director Stock Option (right to buy) | |
| Hollings C. Renton | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2017 | 15,000 | 15,000 | - | - | Director Stock Option (right to buy) | |
| James A. Schoeneck | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2017 | 15,000 | 15,000 | - | - | Director Stock Option (right to buy) | |
| James N. Topper | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2017 | 15,000 | 15,000 | - | - | Director Stock Option (right to buy) | |
| John Schmid | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2017 | 15,000 | 15,000 | - | - | Director Stock Option (right to buy) | |
| Nicholas Lydon | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2017 | 15,000 | 15,000 | - | - | Director Stock Option (right to buy) | |
| Hamza Suria | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2017 | 225,000 | 225,000 | - | - | Employee Stock Option (right to buy) | |
| Marco Londei | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2017 | 110,000 | 110,000 | - | - | Employee Stock Option (right to buy) | |
| Matthew Moyle | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2017 | 75,000 | 75,000 | - | - | Employee Stock Option (right to buy) | |
| Dominic G. Piscitelli | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2017 | 75,000 | 75,000 | - | - | Employee Stock Option (right to buy) | |
| Carol G. Gallagher | None | 31 Jan 2017 | 21,439 | 0 | - | - | Series D Preferred Stock | ||
| Carol G. Gallagher | None | 31 Jan 2017 | 64,296 | 64,296 (0%) | 0% | 0 | Common Stock | ||
| Carol G. Gallagher | None | 31 Jan 2017 | 42,857 | 0 | - | - | Series C Preferred Stock | ||
| James N. Topper | Director, Ten Percent Owner | 31 Jan 2017 | 733,740 | 733,740 (2%) | 2% | 0 | Common Stock | ||
| James N. Topper | Director, Ten Percent Owner | 31 Jan 2017 | 209,095 | 209,095 (1%) | 1% | 0 | Common Stock | ||
| James N. Topper | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 31 Jan 2017 | 311,291 | 1,045,031 (5%) | 1% | 15 | 4,669,365 | Common Stock |
| James N. Topper | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 31 Jan 2017 | 88,709 | 297,804 (1%) | 0% | 15 | 1,330,635 | Common Stock |
| James N. Topper | Director, Ten Percent Owner | 31 Jan 2017 | 209,095 | 0 | - | - | Series D Preferred Stock | ||
| James N. Topper | Director, Ten Percent Owner | 31 Jan 2017 | 733,740 | 0 | - | - | Series D Preferred Stock | ||
| James N. Topper | Director, Ten Percent Owner | 31 Jan 2017 | 195,751 | 0 | - | - | Series C-1 Preferred Stock | ||
| James N. Topper | Director, Ten Percent Owner | 31 Jan 2017 | 604,055 | 0 | - | - | Series C Preferred Stock | ||
| James N. Topper | Director, Ten Percent Owner | 31 Jan 2017 | 1,428,571 | 0 | - | - | Series B Preferred Stock | ||
| James N. Topper | Director, Ten Percent Owner | 31 Jan 2017 | 2,228,377 | 2,228,377 (8%) | 8% | 0 | Common Stock | ||
| Nicholas Lydon | None | 31 Jan 2017 | 67,345 | 0 | - | - | Series D Preferred Stock | ||
| Nicholas Lydon | None | 31 Jan 2017 | 80,877 | 0 | - | - | Series B Preferred Stock | ||
| Nicholas Lydon | None | 31 Jan 2017 | 55,403 | 0 | - | - | Series C Preferred Stock | ||
| Nicholas Lydon | None | 31 Jan 2017 | 203,625 | 270,957 (1%) | 0% | 0 | Common Stock | ||
| Nicholas Lydon | None | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 31 Jan 2017 | 16,666 | 287,623 (1%) | 0% | 15 | 249,990 | Common Stock |
| Hamza Suria | Director, President, CEO | 31 Jan 2017 | 2,020 | 0 | - | - | Series D Preferred | ||
| Hamza Suria | Director, President, CEO | 31 Jan 2017 | 4,998 | 4,998 (0%) | 0% | 0 | Common Stock | ||
| Hamza Suria | Director, President, CEO | 31 Jan 2017 | 2,197 | 0 | - | - | Series C Preferred | ||
| Hamza Suria | Director, President, CEO | 31 Jan 2017 | 781 | 0 | - | - | Series C-1 Preferred | ||
| Marco Londei | Chief Medical Officer | 31 Jan 2017 | 2,020 | 2,020 (0%) | 0% | 0 | Common Stock | ||
| Marco Londei | Chief Medical Officer | 31 Jan 2017 | 2,020 | 0 | - | - | Series D Preferred Stock |